Compare OFAL & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFAL | BIAF |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | 10 | 57 |
| Industry | Military/Government/Technical | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.5M |
| IPO Year | N/A | N/A |
| Metric | OFAL | BIAF |
|---|---|---|
| Price | $0.10 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 553.5K | 295.8K |
| Earning Date | 06-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.23 |
| 52 Week High | $1.78 | $13.50 |
| Indicator | OFAL | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 22.69 | 25.46 |
| Support Level | N/A | $0.61 |
| Resistance Level | $0.27 | $0.87 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 8.03 | 27.49 |
OFA Group, through its subsidiary, provides architectural services, including design and fit-out services for commercial and residential buildings in Hong Kong. The design service includes both the consultation with staff and the actual design work and the company provides a specific conceptualized design with layout plans, detailed design drawings, advice relating to, among other things, budgetary consideration, optimal use of space, the materials, fittings, furniture, appliances and other items to be used to produce a preliminary design plan and quotation. Its works include installing protective materials to cover floors or walls, installing or constructing partition walls, windows, window frames, and decorative fittings, furniture or fixtures, installing plumbing systems, etc.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.